The decisive study for the Covid vaccine candidate from the US biopharmaceutical company Novavax will be delayed by a few weeks.
For approval in the USA and Mexico, phase III of the clinical trial is expected to start in the coming weeks, Novavax announced on Monday in Gaithersburg, Maryland. So far, the company had expected the start by the end of November. Novavax claims to have raised $ 1.6 billion through the US government’s vaccination program to expedite the delivery of a safe and effective vaccine. In Great Britain, around 15,000 participants have now been determined for phase III of the trial study there.
The Novavax share fell 4.5 percent before the IPO. The news meanwhile also weighed on the mood in the German leading index Dax, which then recovered. The US pharmaceutical company Moderna wants to apply for approval for its corona vaccine in the EU this Monday.